107 
Market Cap
As of August 23, 2010: $7,907,000.00
Stock Chart
Progen - 30 Day Poll
Recent BLOGS About Progen Add New
 |
Progens' cash position?
I am also looking at Progen. looking at their announcements I cannot work out their current cash pos… Read more
|
Latest Company News
|
Delisting of Securities of Progen Pharmaceuticals Limited, First National Bancshares Inc. and United American Healthcare Corporation From The NASDAQ Stock Market
MarketWatch - Jul 15, 2010 NEW YORK, Jul 15, 2010 (GlobeNewswire via COMTEX) -- The NASDAQ Stock Market announced today that it will delist the ordinary shares of Progen Pharmaceuticals Limited. Progen Pharmaceuticals ...
|
|
The NASDAQ Stock Market To Delist Ordinary Shares of Progen Pharmaceuticals Limited
Reuters Key Development - Jul 15, 2010 |
|
BRIEF-Progen Pharmaceuticals: received Nasdaq delisting notice
Interactive Investor - Jul 2, 2010 Interactive Investor Trading Limited, trading as "Interactive Investor", is authorised and regulated by the Financial Services Authority. Registered Office: Standon House, 21 Mansell Street ...
|
|
Progen Nasdaq Delisting Update
PR Newswire - Jul 2, 2010 BRISBANE, Australia, July 1 /PRNewswire/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today provided an update relating to the Nasdaq Delisting Notification received on 23 June 2010 ...
Progen Pharma Says It Will Satisfy Minimum Bid Price Requirement In Timeframe Acceptable To Nasdaq - Quick Facts - RTT NewsCorrection: Progen Pharma Says It Will Not Satisfy Minimum Bid Price Requirement In Timeframe Acceptable To Nasdaq - Quick Facts - Stock Markets Review |
|
Progen Pharmaceuticals Limited Announces Updates On Nasdaq Delisting
Reuters Key Development - Jul 1, 2010 |
|
Progen Pharmaceuticals Ltd signs License and Collaboration Agreement with Medigen Biotech Corp.
PharmaLive.com - Jun 30, 2010 Brisbane, Australia, 30th June 2010. Progen Pharmaceuticals Ltd (ASX:PGL, NASDAQ:PGLA) announced today that they had signed a License and Collaboration Agreement with Medigen Biotech Corporation ...
Progen, Medigen Biotech Enter Into Muparfostat License, Collaboration Agreement - Pharmaceutical Business Review |
|
Progen Pharmaceuticals Limited Signs License And Collaboration Agreement With Medigen Biotech Corp.
Reuters Key Development - Jun 30, 2010 |
Website
Videos related to Progen
There are no videos to display.
Company Profile
Cash position at June 30th 2009: approx. $28 million (compared with approx. $76 million in 2008)
Progen Pharmaceuticals Limited (Progen), is engaged in the research and development of small molecule pharmaceuticals, including heparanase inhibitors, that are potent and selective inhibitors of carbohydrate-protein interactions implicated in a range of disease states.
The Company is committed to the discovery, development and commercialization of small molecule therapeutics primarily for the treatment of cancer.
The Company’s three cancer platforms target different aspects of the biology of cancer, such as epigenetics, angiogenesis and cell proliferation.
In February 2008, the Company acquired CellGate, Inc., a Californian based oncology drug development Company
Clinical trials:
Phase 2 trial for PI-88 for muparfostat in metastatic melanoma.
Phase 1a trial for PG11047 is completed and work has started to plan Phase 2 programs investigating PG11047 in indications such as breast cancer, ovarian cancer and prostate cancer.
Terms & Rules
As per ASIC Regulatory Guide 162: All investment tips and comments appearing on this website (Poll results, BLOGS & discussion forums) are submitted by the general public who are not licensed financial advisors. None of the information on this website is financial or investment advice, you should seek independent financial or investment advice by a licensed financial or investment advisor before entering into any position of financial risk. Before using this website, you must agree to the BioInvesting.com.au Terms Of Use